GENE ONLINE|News &
Opinion
Blog

2020-09-18| Technology

Bayer Expands its Metastatic Breast Cancer Treatment

by Judy Ya-Hsuan Lin
Share To

Approximately 70% of women diagnosed with breast cancer are triggered by estrogen receptor (ER) positive disease as well as a 20% survival rate once metastasis occurs. Although the overall progress in breast cancer treatment is on track, the treatment options are still limited, particularly to those suffering from metastatic setting.

By Judy Ya-Hsuan Lin

To increase alternative treatment pathways, Bayer and Systems Oncology signed an exclusive global license agreement to co-develop and commercialize ERSO by making an upfront payment of 25 million and eventually achieving a commercial milestone of 345 million to Systems Oncology.

“The collaboration with Systems Oncology combines their deep experience in identifying alternative treatment pathways with our global footprint and established profile in order to develop new treatment options that can improve patient outcomes,” said Marianne De Backer, PhD, MBA, Member of the Executive Committee and EVP, Head Strategy and Business Development and Licensing, Pharmaceuticals Division of Bayer AG.

Systems Oncology is an AI-based cancer therapy development consisting of a cognitive computing platform and scientists from multidisciplinary scopes to perform highly intelligent integrating, modeling and mining from hundreds of molecular, genome and biomedical databases. According to Dr. Joyce O’Shaughnessy, Baylor University Medical Center, Texas Oncology, US Oncology, “with the experienced team at Bayer leading the development effort, I fully expect that this exciting compound has the potential to create a real paradigm-shift for breast cancer care.”

Related Article: First AI-Designed Drug to Enter Phase I Clinical Trial

The cutting-edge treatment ERSO acts as a small molecule activator of the Unfolded Protein Response (UPR) in ER-positive breast cancer cells. Over the process of development, Systems Oncology collaborated with two professors at the University of Illinois, Dr. David Shapiro and Dr. Paul Hergenrother, both pioneers in the biology and chemistry of anticipatory activators of UPR in breast cancer.

Related Article: AI Drug Pioneer Recursion Pharma Raises $239 Million Led by Leaps By Bayer

References:

1. https://media.bayer.com/baynews/baynews.nsf/id/Bayer-Systems-Oncology-exclusive-license-agreement-innovative-breast-cancer-treatment-approach-ERSO?OpenDocument&sessionID=1600399404

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Merck’s KEYNOTE-522 Success; BMS Licenses PRX019, Prothena Gets $80M
2024-06-19
R&D
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
2024-04-10
AACR Showcases Breakthroughs in Novel Breast Cancer Diagnosis and Treatment Strategies
2024-04-09
LATEST
Merck’s KEYNOTE-522 Success; BMS Licenses PRX019, Prothena Gets $80M
2024-06-19
Pie Medical Imaging announces enrollment completion of the FASTIII clinical trial
2024-06-18
Company Presentations at BIO 2024 Inspire Partnering
2024-06-14
GV Regains Compliance with Nasdaq Minimum Bid Price Requirement
2024-06-13
ARPA-H Fast-Tracks Biotech Startups: Funding Insights from BIO 2024 Panel
2024-06-12
Gene Therapy Innovations and Financial Challenges for the Future of Medicine
2024-06-12
BIO Releases DEI Survey in Partnership with Korn Ferry
2024-06-11
EVENT
Scroll to Top